D-0151-2018 Class II Terminated

Recalled by Pfizer Inc. — New York, NY

FDA drug recall D-0151-2018 was initiated by Pfizer Inc. on Oct 20, 2017 and is designated Class II. Reason for recall: SUPERPOTENT: Weight variations resulting in tablets that are sub and super potent The recall status is terminated (terminated Jun 2, 2020). Affected quantity: 1972 bottles.

Recall details

Product Type
Drugs
Report Date
Jan 10, 2018
Initiation Date
Oct 20, 2017
Termination Date
Jun 2, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1972 bottles

Product description

Zoloft (sertraline HCl) tablets 25 mg* 30-count bottle, Rx only, Distributed by Roerig Division of Pfizer Inc., NY, NY, 10017 NDC 0049-4960-30

Reason for recall

SUPERPOTENT: Weight variations resulting in tablets that are sub and super potent

Distribution pattern

Nationwide in the USA

Code information

Lot: S84026

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0151-2018
openFDA file date
Nov 19, 2026
Loaded by RegDataLab
Nov 20, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Need the full FDA record for Pfizer Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: openFDA record for D-0151-2018. Report a data issue: hello@regdatalab.com.